A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia
Launched by U.S. BIOSCIENCE · Aug 30, 2001
Trial Information
Current as of March 23, 2025
Completed
Keywords
ClinConnect Summary
Patients receive intravenous infusions of trimetrexate glucuronate and leucovorin for 21 days. Leucovorin is continued for 3 additional days after discontinuation of trimetrexate glucuronate. Patients are followed for 1 month.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • Pneumocystis carinii pneumonia (PCP) confirmed within 15 days prior to study entry.
- • Serious intolerance and/or resistance to standard therapies (such as trimethoprim/sulfamethoxazole and parenteral pentamidine) during the course of therapy for the current episode of PCP, OR a documented history of such intolerance during a prior episode.
- • Consent of parent or guardian if less than 18 years of age.
- • Exclusion Criteria
- Patients with the following prior conditions are excluded:
- • History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis), exfoliative dermatitis, or other life-threatening reactions due to trimetrexate glucuronate.
About U.S. Bioscience
U.S. Bioscience is a leading clinical trial sponsor dedicated to advancing innovative therapies and treatments in the biomedical field. With a strong focus on developing solutions for unmet medical needs, the organization leverages cutting-edge research and technology to drive clinical development and ensure patient safety. U.S. Bioscience collaborates with a network of experienced researchers, healthcare professionals, and regulatory bodies to facilitate robust clinical trials that adhere to the highest standards of quality and ethics. Committed to improving health outcomes, U.S. Bioscience strives to bring transformative therapies from the laboratory to the marketplace, enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
West Conshohocken, Pennsylvania, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials